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Gallbladder carcinoma (GBC) is a highly lethal but relatively
rare neoplasm of the digestive tract. Generally speaking,
the overall 5-year survival rate is only 5–15% [1,2]. GBC
also shows an unusual geographic and demographic
distribution. It affects females two to six times more
frequently than males, and its incidence increases with age
[3]. The highest incidences are observed in North and South
America, Poland, and northern India. Low incidences are
seen in Singapore and Nigeria [4]. In Taiwan, GBC is also
uncommon, and 19.2% of cases are associated with a good
operative prognosis [5,6].
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Gallbladder carcinoma (GBC) is a highly lethal but relatively rare neoplasm of the digestive tract. The
progression from gallbladder adenoma to carcinoma remains unclear. The p53 gene is the most frequently
mutated tumor suppressor in human cancers. In this study, we analyzed the expression patterns of the p53
protein in 22 cases of GBC, 17 cases of precursor lesions (16 gallbladder adenomas and 1 cystadenoma), and
15 cases of normal epithelia using immunohistochemical analysis. The results were correlated with
clinicopathologic characteristics. We found that p53 expression was significantly increased in 59.1% (13/22)
of GBC cases and in 17.6% (3/17) of gallbladder adenoma cases (p = 0.009). There was no p53 expression in
the 15 cases of normal epithelia, and a significant difference was shown between normal epithelium and GBC
cases (p < 0.001). In addition, the expression pattern of p53 protein did not show any significant correlation
with the histologic type and the differentiation grade of GBC. In conclusion, we suggest that the aberrant p53
expression may play a role in the occurrence of GBC.
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These differences in the incidence and mortality rates
of GBC suggest that genetic and environmental variables
may be involved in its tumorigenesis. Although there have
been improvements in diagnostic technique, there is,
unfortunately, no promising biomarker that can detect
GBC at an early stage. Thus, most cases are diagnosed at an
advanced stage with a poor outcome.
Recently, it has been demonstrated that the adenoma-
carcinoma sequence is the usual route for the tumorigenesis
of GBC [7–9]. However, there is limited evidence concerning
the possible mechanisms involved in the transformation.
Tumorigenesis is regarded as a multistep process in which
genetic alterations accumulate as premalignant lesions
progress to invasive carcinomas. Among the many known
genetic changes in human carcinogenesis, the most common
is an abnormality in the tumor suppressor gene p53.
Numerous investigators have shown that p53 mutations are
involved in the genesis of many human cancers, including
© 2006 Elsevier. All rights reserved.
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GBC [10,11]. However, the role of p53 in the adenoma-
carcinoma sequence of gallbladder tumorigenesis remains
unclear.
The accumulated literature suggests the oncogenic
properties of p53 brought about by its mutations [12,13].
Mutations in p53 have been found in approximately 50% of
human tumors. One of the most common mechanisms is
point mutation leading to the elevated expression of
conformationally altered and functionally defective p53
proteins. Another is the deletion of one p53 allele, resulting
in the absence of the wild-type p53 protein. Both mechanisms
cause the loss of tumor suppressor function and permit
oncogenesis.
The best way to improve the prognosis of GBC is to
identify and correct the risk factors that may influence its
development. Our objectives were to explore the biologic
properties of gallbladder carcinogenesis and to improve the
prognosis of GBC. In the present study, we examined the
expression pattern of the p53 protein in 54 tissue specimens,
including normal epithelia, precursor lesion, and carcinoma,
by using immunohistochemistry.
MATERIALS AND METHODS
Tissue specimens
Tissues from 22 GBC patients (9 men and 13 women, age
range 38–87 yrs, mean age 66.3 ±  11.3 yrs) and 17
gallbladder adenoma patients (5 men and 12 women,
age range 23–81 yrs, mean age 55.2 ±  16.2 yrs) were
obtained from the Department of Surgery of the
Kaohsiung Medical University Hospital. Furthermore,
15 normal gallbladder tissues, harvested from patients
who underwent right lobectomy to treat hepatocellular
carcinoma, were also included in this study. All of these
specimens were initially fixed in 10% neutral buffered
formalin and then embedded in paraffin after further
dehydration processing.
The precursor lesions of the biliary epithelium were
defined according to Albores-Saavedra et al [14]. Adenoma
is defined as a benign neoplasm, typically polyploidy,
well-demarcated, single, and arises from glandular
epithelium. Cystadenoma is defined as a multiloculated
cystic neoplasm containing mucinous or serous fluid and
lined by columnar epithelium reminiscent of bile duct or
gastric epithelium. GBC is histologically classified
according to the World Health Organization Histological
Classification of Tumors of the Gallbladder and Extrahepatic
Bile Ducts.
Immunohistochemistry
Sections (4 µm thick) were prepared from the representative
tissue blocks on a microtome. Routine immunohistochemistry
procedures were followed as described [15]. In brief, the
slides were deparaffinized with xylene rinse and rehydrated
into distilled water through graded alcohol. Endogenous
peroxidase activity was quenched by 10 minutes of
incubation in a 3% hydrogen peroxide–methanol buffer.
Antigen retrieval was enhanced by autoclaving slides in
sodium citrate buffer (pH 6.0) for 15 minutes and allowing
the solution to cool slowly at room temperature for 20
minutes. The slides were then incubated with primary
mouse monoclonal anti-p53 antibody (Neomarkers) at a
dilution of 1:200 in a humidified chamber for 30 minutes, at
room temperature.
The slides were washed three times in phosphate-
buffered solution and further incubated with biotinylated
secondary antibody for 20 minutes at room temperature.
Antigen-antibody complexes were detected by the avidin-
biotin-peroxidase method using diaminobenzidine as a
chromogenic substrate (DAKO, CA, USA). Finally, the slides
were counterstained with hematoxylin and then examined
by light microscopy.
Interpretation of p53 immunostaining
Immunohistochemical expression levels of p53 were scored
by a semiquantitative method evaluating the intensity and
percentage of positive cells. Only nuclear p53 staining was
regarded as positive staining. Accordingly, the intensity
was graded as absent (0), mild (1), moderate (2), and intense
(3); while the incidence was categorized as absent (0), less
than 10% (1), 10–50% (2), and more than 50% of positive
cells (3). Overall staining score was obtained (range 0–6) by
adding both variables. A score equal to or greater than 3 was
considered as positive for p53 overexpression. In addition,
substituting the primary antibody with the immunoglobulin
fraction of nonimmune mouse serum in grade 3 cases
served as a negative control. Nuclear staining was
determined separately for each specimen, estimated by two
independent pathologists. The rare cases with discordant
scores were re-evaluated and scored on the basis of the
consensual opinion.
Statistical analysis
Statistical differences between categorized groups were
analyzed by the χ2 test and the Fisher’s exact test. All
statistical analyses were performed with SPSS software
package for PC (Version 10.0, SPSS Inc, Chicago, IL, USA). A
p value less than 0.05 was considered statistically significant.
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RESULTS
The expression patterns of the p53 protein in the normal
epithelia, precursor lesions, and GBCs are summarized in
Tables 1 and 2.
We analyzed 17 precursor lesions, including 16
adenomas and 1 biliary cystadenoma (Table 1). According
to the growth pattern, gallbladder adenomas were divided
into three types: tubular, papillary and tubulopapillary.
In this study, all gallbladder adenomas were of tubular
type. Cytologically, of the 16 gallbladder adenomas, 12
cases were pyloric gland type and 4 cases were intestinal
type. Positive p53 immunoreactivity was observed in
16.7% (2/12) (Figure 1) of the pyloric gland type and in
25% (1/4) of the intestinal type. In addition, there was
no p53 immunostaining in gallbladder cystadenoma.
Overall, positive overexpression of p53 protein was
observed in 3 (17.6%) of 17 precursor lesions of the
gallbladder (Table 1).
The 22 GBC cases in our study were of the following
types: 13 adenocarcinoma, 5 papillary adenocarcinoma,
2 adenosquamous carcinoma, 1 mucinous adenocarcinoma,
and 1 clear cell carcinoma (Table 2). We noted that p53
overexpression was predominantly seen in two groups,
adenocarcinoma (Figure 2A) and papillary adenocarcinoma
(Figure 2B), which were 69.2% (9/13) and 60% (3/5),
respectively (Table 2). In contrast, p53 overexpression was
not observed in adenosquamous carcinoma or clear cell
adenocarcinoma specimens. p53 protein was also
overexpressed in cases of mucinous adenocarcinoma
(Figure 2C) and in 59.1% (13/22) of GBCs (Table 1).
According to the differentiation grade, gallbladder
adenocarcinomas were subgrouped into well, moderately,
and poorly differentiated adenocarcinomas. We found
that p53 immunostaining was overexpressed in 50%,
60%, and 83.3% of well, moderately, and poorly
differentiated adenocarcinomas, respectively (Table 2).
Although no significant correlation was shown between
p53 overexpression and differentiation grade, p53
overexpression was relatively higher in the poorly
differentiated adenocarcinoma cases when compared with
well-differentiated cases (Table 2).
Normal gallbladder epithelium was examined in 15
specimens resected from patients with hepatocellular
carcinoma. We found no positive p53 immunoreactivity in
these cases. Meanwhile, normal epithelia in the vicinity of
precursor lesion and GBCs also showed no p53 expression.
A statistically significant difference in p53 protein
overexpression was present between precursor lesions and
Table 2. Correlation of p53 overexpression and histologic
features in gallbladder carcinoma
Histologic features No. tested No. positive
cases (%)
Histologic subtype 22
Adenocarcinoma 13 9 (69.2)
Papillary adenocarcinoma 5 3 (60)
Adenosquamous carcinoma 2 0 (0)
Mucinous adenocarcinoma 1 1 (100)
Clear cell adenocarcinoma 1 0 (0)
Differentiation grade 13
Well differentiated 2 1 (50)
Moderately differentiated 5 3 (60)
Poorly differentiated 6 5 (83.3)
Table 1. The incidence of p53 overexpression in gallbladder
pathologic and normal epithelia
Histologic type Cases tested Positive cases (%)
Carcinoma 22 13 (59.1)*,†
Precursor lesions 17 3 (17.6)
Adenoma 16 3 (18.8)
Pyloric gland type 12 2 (16.7)
Intestinal type 4 1 (25)
Cystadenoma 1 0 (0)
Normal epithelium 15 0 (0)
*p < 0.01 vs normal epithelium; †p < 0.01 vs precursor lesions.
Figure 1. p53 protein overexpression is immunohistochemically detected
in the nuclei (arrow) of pyloric gland adenomas (p53; original
magnification × 20).
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carcinomas of the gallbladder (Table 1, p = 0.009). Similarly,
a statistically significant difference was present between
normal epithelia and carcinomas of the gallbladder
(Table 1, p < 0.001).
DISCUSSION
There is abundant evidence proposing that adenomas are
the premalignant lesions of the gallbladder. Kozuka et al
mentioned that the transition of benign adenoma into
carcinoma is histologically traceable [9]. Thus, some authors
have claimed that the adenoma-carcinoma sequence is the
usual route for tumorigenesis of gallbladder cancers [7–9].
However, there are only limited data about the possible
mechanisms involved in this transformation.
The p53 protein has been demonstrated as a potential
tumor suppressor [16]. The p53 gene is located on the small
arm of chromosome 17 and consists of 11 axons. Mutations
in p53 lead to its inactivation and have been found in 50% of
human tumors. One of the most common mechanisms is
p53 inactivation mediated by point mutation, resulting in
expression of a conformationally altered and functionally
defective p53 protein, which is immunohistochemically
identifiable. On the other hand, a missense mutation or a
deletion of one p53 allele often results in the absence of the
wild-type p53 protein. This causes the loss of tumor suppressor
function and permits the promotion of carcinogenesis.
Carcinogenesis is thought to be a multistep process in
which genetic alterations accumulate as premalignant lesions
progress to invasive carcinomas. Recent reports have shown
that p53 abnormalities are involved in the genesis of GBCs in
high-incidence areas of Japan and Chile [10]. Our study
provides additional information on how p53 abnormalities
may also be involved in the carcinogenesis of GBCs in
Taiwan, a low-incidence area. Aberrant p53 expression may
play a role in the transition from benign adenoma into GBC.
Accumulated data have shown that the majority of
GBCs, which can be of papillary, tubular, mucinous, or
signet cell type, are adenocarcinomas (80–95%). Less
common types include undifferentiated or anaplastic
carcinoma (2–7%), squamous cell carcinoma (1–6%), and
adenosquamous carcinoma (1–4%) [17,18]. Adenocarcinomas
(13/22) were the most common type of GBCs found in our
study (Table 2), followed by papillary adenocarcinomas
(5/22) (Table 2). The remaining tumors include two
adenosquamous carcinomas, one mucinous adenocarcinoma,
and one clear cell adenocarcinoma (Table 2).
Abnormalities of the p53 gene are frequently seen in
gallbladder cancers. Although the frequency of p53
immunostaining in GBC varies widely in different studies
(range, 35–92%), the majority of studies show a frequency
greater than 50% [19]. Well-differentiated tumors have a
better prognosis, while poorly differentiated infiltrative
tumors are more likely to be associated with lymph node
Figure 2. p53 protein overexpression is immunohistochemically detected
in the nuclei of (A) adenocarcinoma, (B) papillary adenocarcinoma, and
(C) mucinous adenocarcinoma. (arrow: positive nuclear staining)
(p53; original magnification × 20).
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metastases and liver invasion. In this study, we showed that
59.1% of GBCs overexpressed p53 protein (Table 1).
Moreover, although our results showed no significant
correlation between p53 overexpression and differentiation
grade, p53 protein overexpression seemed to be more
prominent in cases of poor differentiation grade (Table 2).
The precursor lesions of GBCs are subgrouped by the
classification proposed by Albores-Saavedra et al [14].
Adenoma, a benign glandular tumor, is one of the most
common precursor lesions of the gallbladder [20], with a
reported incidence of 0.4–1.1% in cholecystectomy
specimens. As expected, adenoma constituted the majority
of the precursor lesions (16/17) in our study (Table 1).
Microscopically, there are three growth pattern types for
adenomas: tubular, papillary, and mixed. All of our 16
adenomas were tubular. Cytologically, adenomas can be
further classified into three subtypes: pyloric gland,
intestinal, and biliary. As reported, tubular adenomas of
the pyloric gland type are more common in the gallbladder,
while the intestinal type are more common in the
extrahepatic bile duct [8,21]. In the present study, the pyloric
gland type predominated in 12 of 16 tubular adenomas, and
the remaining 4 adenomas were the intestinal type. Some
studies also described spindle cell metaplasia, which is
occasionally observed in these adenomas. Spindle cell
metaplasias, also called squamoid morules, are characterized
by nodular aggregates of cytologically bland spindle cells
with eosinophilic cytoplasm but without keratinization or
intercellular bridges. Its incidence ranges from 5.3–33.3%
[22]. In our group, we observed squamoid morules in 3
(25%) of 12 pyloric gland adenomas (data not shown).
It has been suggested that two main histologic pathways
exist for the development of gallbladder cancer: (1) the
dysplasia-carcinoma in situ sequence and (2) the adenoma-
carcinoma sequence. Wistuba and Albores-Saavedra [23]
demonstrated the high incidence of p53 overexpression and
its presence in dysplasia, even in specimens with invasive
carcinomas. Therefore, they suggested that dysplasia-
carcinoma in situ is the usual route for gallbladder
carcinogenesis and that p53 abnormality is an important and
early event [19,23]. On the other hand, Watanabe et al [24]
showed a low frequency of p53 overexpression even in the
carcinoma portion of carcinoma-in-adenoma cases (6.3%),
indicating that the adenoma-carcinoma sequence may also
be important. In this study, p53 overexpression was observed
in 18.8% (3/16) of the adenomas, and a statistical difference
exists between adenomas and carcinomas of the gallbladder
(Table 1). It indicated that gallbladder adenomas lack the
p53 abnormalities frequently seen in GBCs.
In conclusion, we suggest that p53 overexpression may
play a role in GBCs in Taiwan. However, this alteration may
not be involved in the putative pathway of gallbladder
carcinogenesis: the adenoma-carcinoma sequence.
Therefore, other mechanisms or variables may be important
in this pathway.
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